Fennebresque Kim S sold $2.9M of BXC (indirect holdings)

Fennebresque Kim S sold 34,138 indirectly-held shares of BlueLinx Holdings Inc. (BXC) at $84.15 ($2.87M total) on 2026-08-06.

Original reporting
SEC EDGAR · Fennebresque Kim S
Published Aug 10, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BXC
Neutral
medium confidence
Mentioned
$BXC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BXCNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 34,138 shares at $84.15 on Aug 6, with holdings after the transaction reported as 0 shares.

02

Market read

Traders may monitor insider selling as a sentiment input, but there is no accompanying guidance, earnings, or operational catalyst in the text.

03

What to watch

The article does not disclose motivations, tax considerations, or whether other insiders are trading, limiting inference from the single transaction.

Relevance 6/10Novelty 4/10Timing: filed Aug 10, transaction dated Aug 6

Background

The article is an SEC Form 4 insider transaction disclosure for BlueLinx Holdings Inc. (BXC).

Company-level read

Ticker impact

$BXCNeutralMedium confidence
Context

BlueLinx Holdings director Fennebresque Kim S sold 34,138 shares in an open-market transaction valued at about $2.87M, per Form 4.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing discloses transaction size and price but provides no new company-specific operating or financial information, and insider sales are often non-informational.

Market effects

Minimal, as the disclosure is company-specific insider activity without sector-wide signals.

None indicated.

None indicated.

Counterpoint

Because the sale is indirect and the filing does not state a 10b5-1 plan, the market may overreact; the sale could be routine liquidity or diversification rather than a bearish signal.

Key entities

  • BlueLinx Holdings Inc.

    Subject of the Form 4 insider transaction disclosure (BXC).

  • Fennebresque Kim S

    Director who sold shares via an open-market sale; reported as indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BXCMed

What BlueLinx (BXC) Said on Its Q3 Earnings Call

BlueLinx (BXC) reported Q3 earnings, with specialty sales up 5% to $550M and structural sales up 18% to $263M. Gross margins improved in both segments. The company expanded supplier relationships and expects Q4 gross margins of 17.5-18.5% for specialty and 9-10% for structural. BlueLinx had $689M in available liquidity and $40M in free cash flow.

$BXCMed

Bluelinx Earnings Call Highlights Growth Amid Market Headwinds

Bluelinx (BXC) reported Q3 net sales of $813M (+8.5% YoY) and adjusted EBITDA of $31.7M (+42% YoY). Gross margins improved to 16.1%. Management highlighted growth in specialty and structural products, but cautioned about market headwinds like weak housing activity and rising costs. Adjusted net income rose 50% to $5.5M, but reported a net loss of $600K.

$BXCMed

BlueLinx Holdings Inc (BXC) Q3 2026 Earnings Call Highlights: Margin Expansion

BlueLinx Holdings Inc (BXC) discussed Q3 2026 earnings, highlighting margin expansion and strategic initiatives. CEO Reddy emphasized channel strategy, pricing, and cost management to mitigate seasonal and market-driven slowdowns. CFO Kelly Wall noted successful price increases and inventory investments for new supplier partnerships. Specialty volumes declined but were offset by pricing. SG&A increased due to acquisitions and higher expenses.

$BXCMed

BlueLinx (BXC) Q3 2026 Earnings Call Transcript

BlueLinx (BXC) reported Q3 2026 net sales of $813M, adjusted EBITDA of $32M (3.9% margin), and adjusted net income of $5.5M. Specialty products drove 70% of net sales and 80% of gross profit. The company expanded partnerships with key suppliers and invested in AI and digital transformation. Despite market challenges, BXC maintained strong liquidity ($689M) and plans to focus on specialty products and strategic growth.

$BXCHigh

BlueLinx Q3 2026 slides: margins expand despite soft housing market

BlueLinx Holdings (NYSE:BXC) reported Q3 2026 earnings of $0.68 per share, beating estimates, with revenue at $813 million. Despite a weak housing market, margins expanded due to pricing strategies and the Disdero acquisition. Stock rose 4.08% to $75.52. Specialty products drove 68% of sales and 78% of gross profit. The company maintains a strong balance sheet with $350 million in cash and expects market challenges to persist.